Jaguar Health (JAGX) Exchanges Preferred Stock for 34,798 Common Share

This summary was generated by AI from the company's SEC filing and may contain errors — always verify against the primary source on SEC.gov.

The short version

Jaguar Health, Inc. (JAGX) entered into an exchange agreement with Streeterville Capital, LLC on June 9, 2026, converting 3.8 shares of Series Q Perpetual Preferred Stock into 34,798 shares of JAGX common stock. The new common shares will be issued free of any restrictive legend. This follows an earlier exchange on May 19, 2026, in which a portion of a royalty interest held by Streeterville was swapped for 408 shares of the same Series Q Preferred Stock.

Jaguar Health, Inc. (Nasdaq: JAGX) filed an 8-K (a form companies use to report major news) on June 18, 2026, disclosing that it has agreed to swap a slice of its preferred stock for common shares with its lender, Streeterville Capital, LLC.

What Happened

According to the filing, JAGX and Streeterville Capital signed an Exchange Agreement dated June 9, 2026. Under the deal, Streeterville will hand back 3.8 shares of Jaguar Health's Series Q Perpetual Preferred Stock — a special class of stock that does not have a set maturity or redemption date — and receive 34,798 shares of JAGX common stock in return. The new common shares will be issued without any trading restrictions.

No cash or other payment changes hands; the only thing Streeterville is giving up is those preferred shares.

Background

The Series Q Preferred Stock itself came from an earlier swap. On May 19, 2026, Jaguar Health and Streeterville exchanged part of a royalty interest (a right to receive a share of future revenue, originally sold to Streeterville on August 24, 2022) for 408 shares of Series Q Preferred Stock. The current agreement converts a small portion — 3.8 of those 408 shares — into common stock.

What It Means for Common Shareholders

When a company issues new common shares, it increases the total number of shares outstanding. This means each existing share represents a slightly smaller piece of the company — a process sometimes called dilution. The filing does not specify the total shares outstanding before or after this transaction, but the 34,798 new shares represent the exchange amount disclosed in the agreement.

Key facts

Jaguar Health, Inc. (JAGX) filed an 8-K on June 18, 2026

Exchange Agreement signed June 9, 2026 between JAGX and Streeterville Capital, LLC

3.8 shares of Series Q Perpetual Preferred Stock exchanged for 34,798 shares of JAGX common stock

Common shares issued free of any restrictive legend

No cash or other consideration paid by Streeterville beyond surrendering the preferred shares

Earlier exchange on May 19, 2026 converted a portion of a royalty interest (originally dated August 24, 2022) into 408 shares of Series Q Preferred Stock

Original royalty interest sold to Streeterville on August 24, 2022

Why it matters

This transaction is part of an ongoing series of debt- and equity-restructuring moves between Jaguar Health and Streeterville Capital that began with a royalty interest sale in 2022. Each conversion of preferred stock into common shares adds to the total number of JAGX common shares in circulation, which can dilute the ownership percentage of existing shareholders. While 34,798 new shares is a small number in isolation, the broader pattern — royalty interest to preferred stock to common stock — signals continued reliance on structured financing arrangements with Streeterville, and retail investors should be aware that further conversions of the remaining preferred shares could follow.

Frequently asked

What did Jaguar Health (JAGX) exchange with Streeterville Capital?

Jaguar Health exchanged 3.8 shares of its Series Q Perpetual Preferred Stock for 34,798 shares of JAGX common stock, which were issued to Streeterville Capital free of any trading restrictions.

Did Jaguar Health receive any money in this deal?

No. According to the filing, no cash or other consideration was paid by Streeterville. The only thing exchanged was the preferred shares for common shares.

How does this affect existing JAGX shareholders?

Issuing 34,798 new common shares increases the total shares outstanding, which slightly reduces the ownership percentage held by existing shareholders — a process known as dilution.

Where did the Series Q Preferred Stock come from originally?

The Series Q Preferred Stock came from a May 19, 2026 exchange in which Jaguar Health converted part of a royalty interest — originally sold to Streeterville on August 24, 2022 — into 408 shares of Series Q Preferred Stock. The current deal converts 3.8 of those 408 shares into common stock.

What the filing reported

1.01 Entry into a Material Agreement

2.03 Creation of a Material Financial Obligation

3.02 Other reported item

9.01 Financial Statements & Exhibits

Jaguar Health (JAGX) Exchanges Preferred Stock for 34,798 Common Shares